Concepedia

Author

Mai Watanabe

Astellas Pharma (Japan)ORCID

Also Known As

Mai Watanabe

13

Publications

309

Citations

9

H-Index

23

Concepts

All Affiliations

Astellas Pharma (Japan)Taisho Pharmaceutical (Japan)
MW

About

Mai Watanabe is an author at Astellas Pharma (Japan) specializing in medicine, pharmacotherapy, and physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

110

2

Pharmacology

3

3

94

3

Immunology

1

1

16

4

Autoimmunity

1

1

16

5

Dendritic Cell Biology

1

1

16

Mai Watanabe

×

7

Publications

261

Citations

7

H-Index

YearCitations

Trialkyltin Compounds Bind Retinoid X Receptor to Alter Human Placental Endocrine Functions

Tsuyoshi Nakanishi, Jun‐ichi Nishikawa, Youhei Hiromori,

Molecular Endocrinology

2005

120

In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats

Toshiki Hatanaka, Masashi Ukai, Mai Watanabe,

Naunyn-Schmiedeberg s Archives of Pharmacology

2012

46

Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats

Toshiki Hatanaka, Masashi Ukai, Mai Watanabe,

Naunyn-Schmiedeberg s Archives of Pharmacology

2012

34

Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents

Mai Watanabe, Brian Marcy, Ayano Hiroki,

The International Journal of Neuropsychopharmacology

2021

19

Application of Microneedles to Skin Induces Activation of Epidermal Langerhans Cells and Dermal Dendritic Cells in Mice

Asuka Takeuchi, Yusuke Nomoto, Mai Watanabe,

Biological and Pharmaceutical Bulletin

2016

16

Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys

Toshiki Hatanaka, Masashi Ukai, Mai Watanabe,

Naunyn-Schmiedeberg s Archives of Pharmacology

2013

14

Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects

Mai Watanabe, Brian Marcy, Kohnosuke Kinoshita,

British Journal of Clinical Pharmacology

2020

12

Page 1